Get to know our clinical trials
Trial of new combinations with immunotherapy in participants with locally advanced/metastatic non-small cell lung cancer.
THE MAIN OBJECTIVE OF THE STUDY IS TO INVESTIGATE THE EFFECTS OF DIFFERENT COMBINATIONS OF DRUGS THAT ACTIVATE THE IMMUNE SYSTEM; AND TO DETERMINE WHETHER THE COMBINATIONS OF DOSTARLIMAB AND GSK4428859A, ARE EFFECTIVE, SAFE AND WHICH DOSE WORKS BEST IN THE TREATMENT OF THEIR DISEASE. THE STUDY WILL ALSO EVALUATE THE ACTIVITY OF DOSTARLIMAB IN MONOTHERAPY.
Technical Summary
- PHASE 2, RANDOMIZED, OPEN-LABEL PLATFORM STUDY USING THE MASTER PROTOCOL TO EVALUATE NEW COMBINATIONS WITH IMMUNOTHERAPY IN PARTICIPANTS WITH LOCALLY ADVANCED/METASTATIC NON-SMALL-CELL LUNG CANCER, SELECTED ACCORDING TO PROGRAMMED DEATH LIGAND 1 EXPRESSION, WHO HAVE NOT RECEIVED PRIOR TREATMENT. IMMUNOTHERAPY
- Code EudraCT: 2021-005115-32
- Protocol number: 213824
- Promoter: GlaxoSmithKline
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.